Life science investor adjusts organization to stay on top of its game
Fresh off of promoting several team members to partners, life science venture capital fund Healthcap's founder Björn Odlander talks about new strategy developments and why pension funds and endowments keep returning to the high-risk sector. He is, however, tight-lipped about past performance.
by MIRZA GAZIC
Swedish venture capital firm Healthcap specializes in investing in companies that try to find and develop medical solutions to serious diseases such as cancer and genetic diseases.
It's a strategy the firm has had for a long time, and the decision was recently made to expand the team and promote several new partners to advance the efforts.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Analyst on Ambu downgrade: Doesn't change investment case
For subscribers
